Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

WITHDRAWN

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Leukemia

Lymphoma

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

PHASE2

Brief Summary

RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the ...

Detailed Description

OBJECTIVES: * Determine the ability of a reduced-intensity conditioning regimen comprising alemtuzumab, fludarabine, and melphalan with or without cyclosporine, mycophenolate mofetil, and low-dose to...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed hematological malignancy of 1 of the following types:
  • Acute myeloid leukemia meeting at least 1 of the following criteria:
  • Poor-risk cytogenetics, including -5, 5q-, -7, 7q-, 11q23, and Philadelphia (Ph) chromosome-positive in first or subsequent complete remission (CR)
  • Relapsed or primary refractory disease with ≤ 10% blasts in the peripheral blood and ≤ 20% blasts in the bone marrow
  • Standard-risk cytogenetics in second CR AND autologous transplantation is not feasible
  • Standard-risk cytogenetics in third or subsequent CR
  • Acute lymphoblastic leukemia meeting 1 of the following criteria:
  • Second or subsequent CR
  • High-risk cytogenetics, including Ph chromosome-positive and t(4:11) in first CR
  • Relapsed or primarily refractory disease with ≤ 10% blasts in the peripheral blood and ≤ 20% blasts in the bone marrow
  • High-risk myelodysplasia
  • International Prognostic Scoring System Score ≥ 2.5
  • Chronic myeloid leukemia (CML)\* with an inadequate response to imatinib meeting 1 of the following criteria:
  • Second or subsequent chronic phase
  • Accelerated phase NOTE: \*Patients with CML in blast crisis (\> 30% promyelocytes and myeloblasts in the bone marrow) are not eligible
  • Non-Hodgkin's lymphoma meeting 1 of the following criteria:
  • Primarily refractory disease or in refractory relapse
  • Relapsed disease after autologous stem cell transplantation
  • Chemosensitive relapsed disease without CR to standard salvage therapy AND no option for autologous stem cell transplantation due to blood or marrow involvement or failure to harvest sufficient autologous stem cells
  • Chronic lymphocytic leukemia meeting both of the following criteria:
  • Stage III or IV disease
  • Refractory to fludarabine
  • Multiple myeloma meeting 1 of the following criteria:
  • Primarily refractory disease or in refractory relapse
  • Relapsed disease after autologous stem cell transplantation
  • No relapsed disease \< 6 months after autologous stem cell transplantation
  • No available eligible HLA-matched (i.e., 5 of 6 or 6 of 6 antigen match for HLA-A, -B, and -DR loci) family donor by serological or molecular typing
  • Available suitable family donor meeting the following criteria:
  • Parent, sibling, or child of the recipient
  • ≥ 16 years of age
  • Identical for only one HLA haplotype (i.e., haploidentical) AND incompatible at the HLA-A, -B, -C, and -DR loci of the unshared haplotype by serological or molecular typing
  • Mismatched with respect to KIR class I epitopes graft-vs-host directional activity
  • Mismatching that predicts both graft-vs-host and host-vs-graft bi-directional activity eligible
  • No mismatching that predicts only host-vs-graft directional activity
  • PATIENT CHARACTERISTICS:
  • Age
  • 18 to 60
  • Performance status
  • ECOG 0-1
  • Hepatic
  • Bilirubin \< 2 times upper limit of normal (ULN)
  • AST and ALT \< 2 times ULN
  • Renal
  • Creatinine ≤ 2 mg/dL
  • Cardiovascular
  • LVEF \> 40% (corrected)
  • Pulmonary
  • DLCO \> 50% of predicted
  • Other
  • No active infection requiring oral or IV antibiotics
  • HIV negative
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • See Disease Characteristics
  • Chemotherapy
  • See Disease Characteristics
  • Endocrine therapy
  • Concurrent corticosteroids allowed for adrenal failure, treatment of graft-vs-host disease, or as premedication during study
  • No concurrent corticosteroids for antiemesis

Exclusion

    Key Trial Info

    Start Date :

    May 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2007

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT00085449

    Start Date

    May 1 2006

    End Date

    January 1 2007

    Last Update

    November 27 2019

    Active Locations (24)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 6 (24 locations)

    1

    Moores UCSD Cancer Center

    La Jolla, California, United States, 92093-0658

    2

    Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center

    Los Angeles, California, United States, 90048

    3

    UCSF Comprehensive Cancer Center

    San Francisco, California, United States, 94115

    4

    CCOP - Christiana Care Health Services

    Newark, Delaware, United States, 19713